Abstract：
Hormone-receptor positive (HR+), Human-Epidermal-growth Factor negative (HER2-) breast cancer, including the Luminal A and the Luminal B subtypes, is the most common in women diagnosed with early-stage BC. Despite the advances in screening, surgery and therapies, recurrence still occurs. Therefore, it is important to identify early those factors that significantly impact the recurrence risk. Based on current evidence and their professional expertise, a Panel of oncologists discussed the definition of high risk of recurrence in early breast cancer. Histological grade, nodal involvement, genomic score, histological grade, tumor size, and Ki-67 proliferation index were rated as the most important factors to define the high risk in patients with early breast cancer. All these factors should be considered comprehensively to tailor the choice of treatment to the peculiar characteristics of each patient.
摘要：
激素受体阳性（HR+），人表皮生长因子阴性（HER2-）乳腺癌，包括管腔A和管腔B亚型，在诊断为早期BC的女性中最常见。尽管筛查取得了进展，手术和治疗，复发仍然发生。因此,重要的是早期发现那些显著影响复发风险的因素.根据目前的证据和他们的专业知识，a肿瘤学家小组讨论了早期乳腺癌高复发风险的定义.组织学分级,节点参与，基因组评分，组织学分级,肿瘤大小,和Ki-67增殖指数被认为是确定早期乳腺癌患者高危的最重要因素。应综合考虑所有这些因素，以根据每个患者的特殊特征选择治疗方法。
